Henry S. Friedman,Michael D. Prados,Patrick Y. Wen,Tom Mikkelsen,David Schiff,Lauren E. Abrey,W.K. Alfred Yung,Nina A. Paleologos,M. Kelly Nicholas,Randy L. Jensen,James J. Vredenburgh,Jane Huang,Maoxia Zheng,Timothy F. Cloughesy
We evaluated the efficacy of bevacizumab, alone and in combination with irinotecan, in patients with recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial.